| Year |
Citation |
Score |
| 2021 |
Moody AS, Dayton PA, Zamboni WC. Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor response. Cancer Drug Resistance (Alhambra, Calif.). 4: 382-413. PMID 34796317 DOI: 10.20517/cdr.2020.94 |
0.325 |
|
| 2021 |
Piha-Paul SA, Thein KZ, De Souza P, Kefford R, Gangadhar T, Smith C, Schuster S, Zamboni WC, Dees CE, Markman B. First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. Investigational New Drugs. PMID 33594602 DOI: 10.1007/s10637-021-01081-x |
0.329 |
|
| 2020 |
Price LSL, Stern ST, Deal AM, Kabanov AV, Zamboni WC. A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics. Science Advances. 6: eaay9249. PMID 32832614 DOI: 10.1126/Sciadv.Aay9249 |
0.387 |
|
| 2020 |
Graham-Gurysh EG, Moore KM, Schorzman AN, Lee T, Zamboni WC, Hingtgen SD, Bachelder EM, Ainslie KM. Tumor Responsive and Tunable Polymeric Platform for Optimized Delivery of Paclitaxel to Treat Glioblastoma. Acs Applied Materials & Interfaces. PMID 32252517 DOI: 10.1021/Acsami.0C04102 |
0.353 |
|
| 2019 |
Lucas AT, Robinson R, Schorzman AN, Piscitelli JA, Razo JF, Zamboni WC. Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients. Antibodies (Basel, Switzerland). 8. PMID 31544809 DOI: 10.3390/Antib8010003 |
0.358 |
|
| 2019 |
Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA, Zamboni WC. Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum] International Journal of Nanomedicine. 14: 5751-5752. PMID 31413572 DOI: 10.2147/Ijn.S207276 |
0.404 |
|
| 2019 |
Parker CL, McSweeney MD, Lucas AT, Jacobs TM, Wadsworth D, Zamboni WC, Lai SK. Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2. Nanomedicine : Nanotechnology, Biology, and Medicine. 102076. PMID 31394261 DOI: 10.1016/J.Nano.2019.102076 |
0.342 |
|
| 2019 |
Taylor SE, Petschauer JS, Donovan H, Schorzman A, Razo J, Zamboni WC, Edwards RP, Zorn KK. Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 29: 147-152. PMID 30640697 DOI: 10.1136/Ijgc-2018-000055 |
0.353 |
|
| 2019 |
Johannessen LH, Hu S, Ke N, D'Ippolito A, Rajagopal N, Marineau J, Savinainen A, Zamboni W, Hodgson G. Abstract C091: Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for clinical development in multiple solid tumor indications Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C091 |
0.432 |
|
| 2019 |
Hwang D, Dismuke T, Rosen E, Kagel J, Lim C, Zamboni W, Kabanov A, Gershon T, Sokolsky-Papkov M. SCIDOT-03. HYPERLOADED POLY(2-OXAZOLINE) MICELLES AS PERSONALIZED DRUG CARRIERS FOR BRAIN TUMORS Neuro-Oncology. 21: vi272-vi273. DOI: 10.1093/Neuonc/Noz175.1144 |
0.329 |
|
| 2018 |
Lucas AT, Price LSL, Schorzman AN, Storrie M, Piscitelli JA, Razo J, Zamboni WC. Factors Affecting the Pharmacology of Antibody-Drug Conjugates. Antibodies (Basel, Switzerland). 7. PMID 31544862 DOI: 10.3390/Antib7010010 |
0.391 |
|
| 2018 |
Starling BR, Kumar P, Lucas AT, Barrow D, Farnan L, Hendrix L, Giovinazzo H, Song G, Gehrig P, Bensen JT, Zamboni WC. Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients. Cancer Chemotherapy and Pharmacology. PMID 30327876 DOI: 10.1007/S00280-018-3702-9 |
0.304 |
|
| 2018 |
Zamboni WC, Szebeni J, Kozlov SV, Lucas AT, Piscitelli JA, Dobrovolskaia MA. Animal models for analysis of immunological responses to nanomaterials: Challenges and considerations. Advanced Drug Delivery Reviews. PMID 30273617 DOI: 10.1016/J.Addr.2018.09.012 |
0.337 |
|
| 2018 |
Schorzman AN, Lucas AT, Kagel JR, Zamboni WC. Methods and Study Designs for Characterizing the Pharmacokinetics and Pharmacodynamics of Carrier-Mediated Agents. Methods in Molecular Biology (Clifton, N.J.). 1831: 201-228. PMID 30051434 DOI: 10.1007/978-1-4939-8661-3_15 |
0.413 |
|
| 2018 |
Sanoff HK, Goldberg RM, Ivanova A, O'Reilly S, Kasbari SS, Kim RD, McDermott R, Moore DT, Zamboni W, Grogan W, Cohn AL, Bekaii-Saab TS, Leonard G, Ryan T, Olowokure OO, et al. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. Cancer. PMID 29905927 DOI: 10.1002/Cncr.31552 |
0.31 |
|
| 2018 |
McSweeney MD, Wessler T, Price LSL, Ciociola EC, Herity LB, Zamboni WC, Forest MG, Cao Y, Lai SK. A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 29879519 DOI: 10.1016/J.Jconrel.2018.06.002 |
0.37 |
|
| 2018 |
Byrne JD, Jajja MRN, O'Neill AT, Schorzman AN, Keeler AW, Luft JC, Zamboni WC, DeSimone JM, Yeh JJ. Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer. Cancer Chemotherapy and Pharmacology. PMID 29603014 DOI: 10.1007/S00280-018-3570-3 |
0.347 |
|
| 2017 |
McRee AJ, Marcom PK, Moore DT, Zamboni WC, Kornblum ZA, Hu Z, Phipps R, Anders CK, Reeder-Hayes K, Carey LA, Weck KE, Perou CM, Dees EC. A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clinical Breast Cancer. PMID 29153866 DOI: 10.1016/J.Clbc.2017.10.014 |
0.317 |
|
| 2017 |
Risselada M, Linder KE, Griffith E, Roberts BV, Davidson G, Zamboni WC, Messenger KM. Pharmacokinetics and toxicity of subcutaneous administration of carboplatin in poloxamer 407 in a rodent model pilot study. Plos One. 12: e0186018. PMID 28982137 DOI: 10.1371/Journal.Pone.0186018 |
0.308 |
|
| 2017 |
Madden AJ, Oberhardt B, Lockney D, Santos C, Vennam P, Arney D, Franzen S, Lommel SA, Miller CR, Gehrig P, Zamboni WC. Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancer. Nanomedicine (London, England). PMID 28952882 DOI: 10.2217/Nnm-2016-0421 |
0.33 |
|
| 2017 |
Lucas AT, Price LS, Schorzman A, Zamboni WC. Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents. Nanomedicine (London, England). PMID 28745129 DOI: 10.2217/Nnm-2017-0101 |
0.441 |
|
| 2017 |
Lucas AT, Herity LB, Kornblum ZA, Madden AJ, Gabizon A, Kabanov AV, Ajamie RT, Bender DM, Kulanthaivel P, Sanchez-Felix MV, Havel HA, Zamboni WC. Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugs. International Journal of Pharmaceutics. PMID 28473237 DOI: 10.1016/J.Ijpharm.2017.04.079 |
0.351 |
|
| 2017 |
Perry JL, Reuter KG, Luft JC, Pecot CV, Zamboni WC, DeSimone JM. Mediating Passive Tumor Accumulation through Particle Size, Tumor Type and Location. Nano Letters. PMID 28287740 DOI: 10.1021/Acs.Nanolett.7B00021 |
0.367 |
|
| 2017 |
Chang SX, Rivera JN, Herity LB, Price LS, Madden AJ, Roques JR, Santos C, Darr D, Zamboni WC. Abstract 5051: Comparison of microbeam versus conventional broadbeam radiation therapy on tumor delivery enhancement of PEGylated liposomal doxorubicin in a triple negative breast cancer mouse model Cancer Research. 77: 5051-5051. DOI: 10.1158/1538-7445.Am2017-5051 |
0.347 |
|
| 2016 |
Lucas AT, White TF, Deal AM, Herity LB, Song G, Santos CM, Zamboni WC. Profiling the relationship between tumor-associated macrophages and pharmacokinetics of liposomal agents in preclinical murine models. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 27720926 DOI: 10.1016/J.Nano.2016.09.015 |
0.405 |
|
| 2016 |
Song G, Suzuki OT, Santos CM, Lucas AT, Wiltshire T, Zamboni WC. Gulp1 Is Associated with the Pharmacokinetics of PEGylated Liposomal Doxorubicin (PLD) in Inbred Mouse Strains. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 27288666 DOI: 10.1016/J.Nano.2016.05.019 |
0.306 |
|
| 2016 |
Patel NR, Piroyan A, Nack AH, Galati CA, McHugh M, Orosz S, Keeler AW, O 'Neal S, Zamboni WC, Davis B, Coleman TP. Design, Synthesis and Characterization of Folate-Targeted Platinum Theranostic Nanoemulsions for Therapy and Imaging of Ovarian Cancer. Molecular Pharmaceutics. PMID 27170232 DOI: 10.1021/Acs.Molpharmaceut.6B00149 |
0.331 |
|
| 2016 |
Lucas AT, Madden AJ, Zamboni WC. Challenges in preclinical to clinical translation for anticancer carrier-mediated agents. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology. PMID 26846457 DOI: 10.1002/Wnan.1394 |
0.425 |
|
| 2016 |
Giovinazzo H, Kumar P, Sheikh A, Brooks KM, Ivanovic M, Walsh M, Caron WP, Kowalsky RJ, Song G, Whitlow A, Clarke-Pearson DL, Brewster WR, Van Le L, Zamboni BA, Bae-Jump V, ... ... Zamboni WC, et al. Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer. Cancer Chemotherapy and Pharmacology. PMID 26822231 DOI: 10.1007/S00280-015-2945-Y |
0.323 |
|
| 2016 |
Lucas AT, O'Neal SK, Santos CM, White TF, Zamboni WC. A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues. Journal of Pharmaceutical and Biomedical Analysis. 119: 122-9. PMID 26678179 DOI: 10.1016/J.Jpba.2015.11.035 |
0.391 |
|
| 2016 |
Markman B, Souza PLD, Dees EC, Gangadhar TC, Cooper A, Roohullah A, Boolell V, Zamboni W, Murphy C, Senderowicz AM, Wang H. A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors. Journal of Clinical Oncology. 34: 2526-2526. DOI: 10.1200/Jco.2016.34.15_Suppl.2526 |
0.449 |
|
| 2016 |
Zamboni WC, Markman B, Souza Pd, Dees EC, Gangadhar T, Eliasof S, Murphy C, Senderowicz A, Wang H. Abstract 2047: Pharmacokinetics (PK) of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing the payload docetaxel, in patients with refractory solid tumors Cancer Research. 76: 2047-2047. DOI: 10.1158/1538-7445.Am2016-2047 |
0.435 |
|
| 2016 |
Hartman LK, Dhruv HD, Householder KT, Roth JE, Schorzman AN, Zamboni W, Sirianni R, Berens ME. Abstract 1329: Intravenous delivery of Erlotinib-loaded PLA-PEG nanoparticles for treatment of GB Cancer Research. 76: 1329-1329. DOI: 10.1158/1538-7445.Am2016-1329 |
0.403 |
|
| 2016 |
Wang H, Markman B, Souza Pd, Dees EC, Gangadhar TC, Piha-Paul SA, Zamboni WC, Murphy C, Senderowicz A. A dose-escalation study of weekly intravenous CRLX301 in patients with advanced solid tumor malignancies Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw368.56 |
0.4 |
|
| 2016 |
Wang H, Zamboni W, Tolcher A, Lakhani N, Piha-Paul SA, Caliri K, Crowell T, Senderowicz A. Pharmacokinetics (PK) of CRLX101 administered weekly in patients (pts) with advanced solid tumors Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw368.37 |
0.392 |
|
| 2015 |
Kai MP, Brighton HE, Fromen CA, Shen TW, Luft JC, Luft YE, Keeler AW, Robbins GR, Ting JP, Zamboni WC, Bear JE, DeSimone JM. Tumor Presence Induces Global Immune Changes and Enhances Nanoparticle Clearance. Acs Nano. PMID 26592524 DOI: 10.1021/Acsnano.5B05999 |
0.346 |
|
| 2015 |
Lucas AT, Madden AJ, Zamboni WC. Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents. Expert Opinion On Drug Metabolism & Toxicology. 11: 1419-33. PMID 26173794 DOI: 10.1517/17425255.2015.1057496 |
0.397 |
|
| 2015 |
Chang SX, Madden AJ, Rivera JN, Santos CM, Hunter LM, Darr DB, Zamboni WC. WE-EF-BRA-09: Microbeam Radiation Therapy Enhances Tumor Drug Uptake of PEGylated Liposomal Doxorubicin (PLD) in a Triple Negative Breast Cancer GEM Model. Medical Physics. 42: 3676. PMID 26129287 DOI: 10.1118/1.4925988 |
0.441 |
|
| 2015 |
Taylor SE, Li R, Petschauer JS, Donovan H, O'Neal S, Keeler AW, Zamboni WC, Edwards RP, Zorn KK. Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer. Gynecologic Oncology. PMID 26111788 DOI: 10.1016/J.Ygyno.2015.06.026 |
0.375 |
|
| 2015 |
Song G, Tarrant TK, White TF, Barrow DA, Santos CM, Timoshchenko RG, Hanna SK, Ramanathan RK, Lee CR, Bae-Jump VL, Gehrig PA, Zamboni WC. Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 26093057 DOI: 10.1016/J.Nano.2015.05.007 |
0.425 |
|
| 2015 |
Kai MP, Keeler AW, Perry JL, Reuter KG, Luft JC, O'Neal SK, Zamboni WC, DeSimone JM. Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle. Journal of Controlled Release : Official Journal of the Controlled Release Society. 204: 70-7. PMID 25744827 DOI: 10.1016/J.Jconrel.2015.03.001 |
0.445 |
|
| 2015 |
Ganta S, Singh A, Kulkarni P, Keeler AW, Piroyan A, Sawant RR, Patel NR, Davis B, Ferris C, O'Neal S, Zamboni W, Amiji MM, Coleman TP. EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy. Pharmaceutical Research. 32: 2753-63. PMID 25732960 DOI: 10.1007/S11095-015-1660-Z |
0.34 |
|
| 2015 |
Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA, Zamboni WC. Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. International Journal of Nanomedicine. 10: 1201-9. PMID 25709442 DOI: 10.2147/Ijn.S62911 |
0.372 |
|
| 2015 |
Petschauer JS, Madden AJ, Kirschbrown WP, Song G, Zamboni WC. The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents. Nanomedicine (London, England). 10: 447-63. PMID 25707978 DOI: 10.2217/Nnm.14.179 |
0.412 |
|
| 2015 |
Byrne JD, Jajja MR, O'Neill AT, Bickford LR, Keeler AW, Hyder N, Wagner K, Deal A, Little RE, Moffitt RA, Stack C, Nelson M, Brooks CR, Lee W, Luft JC, ... ... Zamboni WC, et al. Local iontophoretic administration of cytotoxic therapies to solid tumors. Science Translational Medicine. 7: 273ra14. PMID 25653220 DOI: 10.1126/Scitranslmed.3009951 |
0.313 |
|
| 2015 |
Byrne JD, Jajja MR, Schorzman AN, Keeler AW, O'Neill AT, Luft JC, Zamboni WC, DeSimone JM, Yeh JJ. Abstract A95: Local iontophoretic delivery of FOLFIRINOX minimizes systemic toxicity for the treatment of pancreatic cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-A95 |
0.407 |
|
| 2015 |
Chang XS, Madden AJ, Rivera J, Santos C, Darr D, Hunter L, Zamboni WC. Abstract 4516: The effects of microbeam radiation therapy on the pharmacokinetics of PEGylated liposomal doxorubicin in a triple negative breast cancer GEM model Cancer Research. 75: 4516-4516. DOI: 10.1158/1538-7445.Am2015-4516 |
0.457 |
|
| 2015 |
Taylor SE, Li R, Petschauer JS, Donovan HD, Zamboni WC, Edwards RP, Zorn KK. Phase I study of intravenous (IV) oxaliplatin and intraperitoneal (IP) docetaxel in recurrent ovarian and primary peritoneal cancer Gynecologic Oncology. 137: 148. DOI: 10.1016/J.Ygyno.2015.01.370 |
0.316 |
|
| 2014 |
Madden AJ, Rawal S, Sandison K, Schell R, Schorzman A, Deal A, Feng L, Ma P, Mumper R, DeSimone J, Zamboni WC. Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT). Journal of Nanoparticle Research : An Interdisciplinary Forum For Nanoscale Science and Technology. 16. PMID 26392803 DOI: 10.1007/S11051-014-2662-1 |
0.433 |
|
| 2014 |
Song G, Darr DB, Santos CM, Ross M, Valdivia A, Jordan JL, Midkiff BR, Cohen S, Nikolaishvili-Feinberg N, Miller CR, Tarrant TK, Rogers AB, Dudley AC, Perou CM, Zamboni WC. Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6083-95. PMID 25231403 DOI: 10.1158/1078-0432.Ccr-14-0493 |
0.397 |
|
| 2014 |
Peng L, Schorzman AN, Ma P, Madden AJ, Zamboni WC, Benhabbour SR, Mumper RJ. 2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model. International Journal of Nanomedicine. 9: 3601-10. PMID 25114529 DOI: 10.2147/Ijn.S66040 |
0.395 |
|
| 2014 |
Chu KS, Finniss MC, Schorzman AN, Kuijer JL, Luft JC, Bowerman CJ, Napier ME, Haroon ZA, Zamboni WC, DeSimone JM. Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicity. Nano Letters. 14: 1472-6. PMID 24552251 DOI: 10.1021/Nl4046558 |
0.382 |
|
| 2014 |
Schell RF, Sidone BJ, Caron WP, Walsh MD, White TF, Zamboni BA, Ramanathan RK, Zamboni WC. Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents. Nanomedicine : Nanotechnology, Biology, and Medicine. 10: 109-17. PMID 23891988 DOI: 10.1016/J.Nano.2013.07.005 |
0.373 |
|
| 2014 |
Taylor SE, Li R, Petschauer JS, Donovan H, Zamboni WC, Edwards RP, Zorn KK. Abstract CT412: Phase I study of intraveneous docetaxel and intraperitoneal oxaliplatin in recurrent ovarian, fallopian tube and peritoneal cancer Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct412 |
0.4 |
|
| 2013 |
Ko EM, Lippmann Q, Caron WP, Zamboni W, Gehrig PA. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients. Gynecologic Oncology. 131: 683-688. PMID 24096112 DOI: 10.1016/J.Ygyno.2013.09.031 |
0.34 |
|
| 2013 |
Caron WP, Lay JC, Fong AM, La-Beck NM, Kumar P, Newman SE, Zhou H, Monaco JH, Clarke-Pearson DL, Brewster WR, Van Le L, Bae-Jump VL, Gehrig PA, Zamboni WC. Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology. The Journal of Pharmacology and Experimental Therapeutics. 347: 599-606. PMID 24042160 DOI: 10.1124/Jpet.113.208801 |
0.354 |
|
| 2013 |
Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA, Zamboni WC. Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors European Journal of Clinical Pharmacology. 69: 2073-2081. PMID 23989300 DOI: 10.1007/S00228-013-1580-Y |
0.432 |
|
| 2013 |
Chu KS, Schorzman AN, Finniss MC, Bowerman CJ, Peng L, Luft JC, Madden AJ, Wang AZ, Zamboni WC, DeSimone JM. Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy. Biomaterials. 34: 8424-9. PMID 23899444 DOI: 10.1016/J.Biomaterials.2013.07.038 |
0.332 |
|
| 2013 |
Usary J, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, Karginova O, Jordan J, Combest A, Bridges A, Prat A, Cheang MC, Herschkowitz JI, Rosen JM, Zamboni W, et al. Predicting drug responsiveness in human cancers using genetically engineered mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4889-99. PMID 23780888 DOI: 10.1158/1078-0432.Ccr-13-0522 |
0.393 |
|
| 2013 |
Caron WP, Morgan KP, Zamboni BA, Zamboni WC. A review of study designs and outcomes of phase I clinical studies of nanoparticle agents compared with small-molecule anticancer agents. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3309-15. PMID 23620407 DOI: 10.1158/1078-0432.Ccr-12-3649 |
0.364 |
|
| 2013 |
Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Research. 73: 2412-7. PMID 23423979 DOI: 10.1158/0008-5472.Can-12-4561 |
0.422 |
|
| 2013 |
Zhang Y, Sadgrove MP, Sueda K, Yang YT, Pacyniak EK, Kagel JR, Braun BA, Zamboni WC, Mumper RJ, Jay M. Nonaqueous gel for the transdermal delivery of a DTPA penta-ethyl ester prodrug. The Aaps Journal. 15: 523-32. PMID 23389812 DOI: 10.1208/S12248-013-9459-5 |
0.339 |
|
| 2013 |
Byrne J, O'Neill A, Jajja R, Napier M, Luft JC, Zamboni W, Yeh JJ, DeSimone J. Abstract 5610: Electric-field assisted delivery of gemcitabine for the treatment of pancreatic cancer. Cancer Research. 73: 5610-5610. DOI: 10.1158/1538-7445.Am2013-5610 |
0.398 |
|
| 2013 |
Madden AJ, Rawal S, Chu K, Sandison K, Schell R, Feng L, Ma P, Mumper R, DeSimone J, Zamboni WC. Abstract 3355: Evaluation of the efficiency of tumor and tissue delivery of carrier mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric relative distribution index over time (RDI-OT). Cancer Research. 73: 3355-3355. DOI: 10.1158/1538-7445.Am2013-3355 |
0.441 |
|
| 2013 |
Song G, Darr DB, Santos CM, White TF, Jordan JL, Kim M, Midkiff BR, Feinberg NN, Miller R, Rogers AB, Dudley AC, Perou CM, Zamboni WC. Abstract 3354: Relationship between tumor-associated macrophages (TAMs), tumor delivery, and efficacy of PEGylated liposomal doxorubicin (PLD) and non-liposomal doxorubicin (NL-doxo) in genetically engineered mouse models (GEMMs) of breast cancer (BC). Cancer Research. 73: 3354-3354. DOI: 10.1158/1538-7445.Am2013-3354 |
0.402 |
|
| 2012 |
Wu H, Ramanathan RK, Zamboni BA, Strychor S, Ramalingam S, Edwards RP, Friedland DM, Stoller RG, Belani CP, Maruca LJ, Bang YJ, Zamboni WC. Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients. International Journal of Nanomedicine. 7: 5555-64. PMID 23112576 DOI: 10.2147/Ijn.S35751 |
0.323 |
|
| 2012 |
Combest AJ, Roberts PJ, Dillon PM, Sandison K, Hanna SK, Ross C, Habibi S, Zamboni B, Müller M, Brunner M, Sharpless NE, Zamboni WC. Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors. The Oncologist. 17: 1303-16. PMID 22993143 DOI: 10.1634/Theoncologist.2012-0274 |
0.42 |
|
| 2012 |
Infante JR, Keedy VL, Jones SF, Zamboni WC, Chan E, Bendell JC, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg ML, Burris HA. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology. 70: 699-705. PMID 22941375 DOI: 10.1200/Jco.2009.27.15_Suppl.2547 |
0.389 |
|
| 2012 |
Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest AJ, Jin J, Zamboni WC, Johnson GL, Perou CM, Sharpless NE. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5290-303. PMID 22872574 DOI: 10.1158/1078-0432.Ccr-12-0563 |
0.363 |
|
| 2012 |
Zamboni WC, Torchilin V, Patri AK, Hrkach J, Stern S, Lee R, Nel A, Panaro NJ, Grodzinski P. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3229-41. PMID 22669131 DOI: 10.1158/1078-0432.Ccr-11-2938 |
0.41 |
|
| 2012 |
Caron WP, Song G, Kumar P, Rawal S, Zamboni WC. Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier‐Mediated Anticancer Agents Clinical Pharmacology & Therapeutics. 91: 802-812. PMID 22472987 DOI: 10.1038/Clpt.2012.12 |
0.4 |
|
| 2012 |
Walsh MD, Hanna SK, Sen J, Rawal S, Cabral CB, Yurkovetskiy AV, Fram RJ, Lowinger TB, Zamboni WC. Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2591-602. PMID 22392910 DOI: 10.1158/1078-0432.Ccr-11-1554 |
0.425 |
|
| 2012 |
Song G, Wu H, Yoshino K, Zamboni WC. Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. Journal of Liposome Research. 22: 177-92. PMID 22332871 DOI: 10.3109/08982104.2012.655285 |
0.343 |
|
| 2012 |
La-Beck NM, Zamboni BA, Gabizon A, Schmeeda H, Amantea M, Gehrig PA, Zamboni WC. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemotherapy and Pharmacology. 69: 43-50. PMID 21590446 DOI: 10.1007/S00280-011-1664-2 |
0.338 |
|
| 2012 |
Wu H, Ramanathan RK, Zamboni BA, Strychor S, Ramalingam S, Edwards RP, Friedland DM, Stoller RG, Belani CP, Maruca LJ, Bang YJ, Zamboni WC. Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Journal of Clinical Pharmacology. 52: 180-94. PMID 21233302 DOI: 10.1177/0091270010394851 |
0.387 |
|
| 2012 |
Giovinazzo H, Kumar P, Sheikh A, Ivanovic M, Walsh MD, Caron WP, Song G, Whitlow AB, Newman SE, La-Beck NM, Kowalsky RJ, Zamboni BA, Clarke-Pearson DL, Brewster WR, Le LV, ... ... Zamboni W, et al. Technetium-99m sulfur colloid (TSC) as a phenotypic probe for predicting pharmacokinetics (PK) and palmar-plantar erythrodysesthesia (PPE) toxicity of pegylated liposomal doxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer (EOC). Journal of Clinical Oncology. 30: 5050-5050. DOI: 10.1200/Jco.2012.30.15_Suppl.5050 |
0.362 |
|
| 2012 |
Caron WP, Lay JC, Kumar P, Fong AM, La-Beck NM, Newman SE, Clarke-Pearson DL, Brewster WR, Le LV, Bae-Jump VL, Gehrig PA, Zamboni W. Cellular function of the mononuclear phagocyte system (MPS) as a phenotypic probe for pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. Journal of Clinical Oncology. 30: 2591-2591. DOI: 10.1200/Jco.2012.30.15_Suppl.2591 |
0.382 |
|
| 2012 |
Song G, Tarrant TK, Barrow DA, Gehrig PA, Hanna SK, Strychor S, Ramalingam S, Belani C, Edwards RP, Ramanathan RK, Zamboni WC. Abstract 754: The effect of CC chemokine ligand-2 (CCL2/MCP-1) and CC chemokine ligand-5 (CCL5/RANTES) on the pharmacokinetics (PK) and the pharmacodynamics (PD) of pegylated liposomal CKD602 (S-CKD602) in patients with advanced solid tumors Cancer Research. 72: 754-754. DOI: 10.1158/1538-7445.Am2012-754 |
0.366 |
|
| 2012 |
La-Beck NM, Walko CM, Scoggins L, Dees EC, Orlowski RZ, Wu H, Amantea M, Fardin M, Zamboni W. Abstract 3768: Evaluating the effects of bortezomib (Velcade®) on the pharmacokinetics (PK) of pegylated liposomal doxorubicin (Doxil®, PLD) Cancer Research. 72: 3768-3768. DOI: 10.1158/1538-7445.Am2012-3768 |
0.381 |
|
| 2012 |
Kumar P, Caron WP, Song G, Gallagher K, Clarke-Pearson DL, Brewster WR, Le LV, Bae-Jump V, Gehrig PA, Zamboni WC. Abstract 2673: Relationship between serum hormone levels and pharmacokinetics (PK) of PEGylated liposomal doxorubicin (PLD) in patients with refractory ovarian cancer Cancer Research. 72: 2673-2673. DOI: 10.1158/1538-7445.Am2012-2673 |
0.39 |
|
| 2011 |
Caron WP, Lay JC, Fong AM, La-Beck NM, Newman SE, Clarke-Pearson DL, Brewster WR, Van Le L, Bae-Jump VL, Gehrig PA, Zamboni W. Cellular function of the mononuclear phagocyte system (MPS) as a phenotypic probe for pegylated liposomal doxorubicin (PLD) pharmacokinetics (PK) in patients with recurrent ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2550. PMID 28022305 DOI: 10.1200/Jco.2011.29.15_Suppl.2550 |
0.381 |
|
| 2011 |
Walsh MD, Giovinazzo H, Sheikh A, Ivanovic M, Whitlow AB, Newman SE, La-Beck NM, Kowalsky RJ, Zamboni BA, Clarke-Pearson DL, Brewster WR, Van Le L, Bae-Jump VL, Gehrig PA, Zamboni W. Technetium-99m sulfur colloid (TSC) as a phenotypic probe for the pharmacokinetics (PK) and pharmacodynamics (PD) of pegylated liposomal doxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer (EOC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2582. PMID 28022256 DOI: 10.1200/Jco.2011.29.15_Suppl.2582 |
0.321 |
|
| 2011 |
Caron WP, Clewell H, Dedrick R, Ramanathan RK, Davis WL, Yu N, Tonda M, Schellens JH, Beijnen JH, Zamboni WC. Allometric scaling of pegylated liposomal anticancer drugs. Journal of Pharmacokinetics and Pharmacodynamics. 38: 653-69. PMID 21863380 DOI: 10.1007/S10928-011-9213-5 |
0.359 |
|
| 2011 |
Zamboni WC, Combest AJ, DeLoia JA, Edwards RP, Bridges AS, Zamboni BA, Walko CM, Yu AY, Krivak TC, Kelley JL. Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer. Cancer Chemotherapy and Pharmacology. 68: 1255-62. PMID 21437702 DOI: 10.1007/S00280-011-1609-9 |
0.321 |
|
| 2011 |
Zamboni WC, Maruca LJ, Strychor S, Zamboni BA, Ramalingam S, Edwards RP, Kim J, Bang Y, Lee H, Friedland DM, Stoller RG, Belani CP, Ramanathan RK. Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. Journal of Liposome Research. 21: 158-65. PMID 20626314 DOI: 10.3109/08982104.2010.496085 |
0.312 |
|
| 2011 |
Zamboni WC, Eiseman JL, Strychor S, Rice PM, Joseph E, Zamboni BA, Donnelly MK, Shurer J, Parise RA, Tonda ME, Yu NY, Basse PH. Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models. Journal of Liposome Research. 21: 70-80. PMID 20528623 DOI: 10.3109/08982101003754385 |
0.38 |
|
| 2011 |
Sidone B, Zamboni BA, Zamboni W. Meta-analysis of the pharmacokinetic variability of liposomal anticancer agents compared with nonliposomal anticancer agents. Journal of Clinical Oncology. 29: 2583-2583. DOI: 10.1200/Jco.2011.29.15_Suppl.2583 |
0.316 |
|
| 2011 |
Caron WP, Clewell H, Dedrick R, Ramanathan RK, Yu N, Schellens JH, Beijnen JH, Zamboni WC. Abstract 373: Allometric scaling of the pharmacokinetics of pegylated liposomal anticancer drugs Cancer Research. 71: 373-373. DOI: 10.1158/1538-7445.Am2011-373 |
0.397 |
|
| 2011 |
Morgan KP, Caron WP, Walsh MD, Zamboni BA, Zamboni WC. Abstract 371: Comparison of toxicity and study design issues of nanoparticle and small molecule anticancer agents in preclinical models and phase I clinical trials Cancer Research. 71: 371-371. DOI: 10.1158/1538-7445.Am2011-371 |
0.429 |
|
| 2011 |
Schell RF, Caron WP, Walsh MD, Zamboni BA, Ramanathan RK, Zamboni WC. Abstract 1295: Relationship between pharmacokinetic (PK) sampling schema and reported PK variability of liposomes in patients Cancer Research. 71: 1295-1295. DOI: 10.1158/1538-7445.Am2011-1295 |
0.402 |
|
| 2011 |
Anders C, Adamo B, Walsh, Karginova O, Darr D, Deal A, Santos C, Bash R, Hanna S, Carey L, Miller C, Sharpless N, Zamboni W. P4-17-04: Pharmacokinetic Disposition of PEGylated Liposomal Doxorubicin Compared with Non-Liposomal Doxorubicin in an Intracranial Breast Cancer Murine Model. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P4-17-04 |
0.449 |
|
| 2010 |
Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2760-8. PMID 20460479 DOI: 10.1158/1078-0432.Ccr-09-3199 |
0.331 |
|
| 2010 |
La-Beck NM, Wu H, Infante JR, Jones SF, Burris HA, Keedy VL, Kodaira H, Ikeda S, Ramanathan RK, Zamboni W. The evaluation of gender on the pharmacokinetics (PK) of pegylated liposomal anticancer agents. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E13003 |
0.417 |
|
| 2010 |
Combest AJ, Zorn KK, Edwards RP, Hanna SK, Habibi S, Strange M, Zamboni B, Krivak TC, Sukurmvanich P, Zamboni W. Pharmacokinetics (PK) of oxaliplatin (OX) after intraperitoneal (IP) and intravenous (IV) administration in patients with gynecological malignancies. Journal of Clinical Oncology. 28: 2584-2584. DOI: 10.1200/Jco.2010.28.15_Suppl.2584 |
0.364 |
|
| 2010 |
Song G, Wu H, La-Beck NM, Zamboni BA, Srychor S, Santory MM, Deither SR, Zamboni WC. Abstract 3700: Effect of gender on pharmacokinetic disposition of pegylated liposomal CKD-602 (S-CKD602) and optisomal topotecan (TLI) in rats Cancer Research. 70: 3700-3700. DOI: 10.1158/1538-7445.Am10-3700 |
0.332 |
|
| 2010 |
Caron WP, La-Beck NM, Fong AM, Liu P, Hanna SK, Ngo TL, Zamboni BA, Gehrig PA, Tarrant T, Zamboni WC. Abstract 3697: Evaluation of monocyte and granulocyte function with and without ex vivo pegylated liposomal doxorubicin (PLD) exposure in blood of healthy volunteers Cancer Research. 70: 3697-3697. DOI: 10.1158/1538-7445.Am10-3697 |
0.33 |
|
| 2010 |
Walsh MD, Hanna SK, Sen JM, Benson JD, Cabral CB, Yurkovetskiy A, Lowinger TB, Zamboni BA, Zamboni WC. Abstract 3696: Pharmacokinetics (PK) of XMT-1001, a novel polymeric prodrug of camptothecin, in mice bearing HT-29 human colon carcinoma xenografts Cancer Research. 70: 3696-3696. DOI: 10.1158/1538-7445.Am10-3696 |
0.419 |
|
| 2009 |
Wu H, Ramanathan RK, Srychor S, Zamboni BA, Ramalingam S, Edwards RP, Friedland DM, Stoller RG, Belani CP, Zamboni WC. Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2545. PMID 27961861 DOI: 10.1200/Jco.2009.27.15_Suppl.2545 |
0.339 |
|
| 2009 |
Zamboni WC, Strychor S, Maruca L, Ramalingam S, Zamboni BA, Wu H, Friedland DM, Edwards RP, Stoller RG, Belani CP, Ramanathan RK. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies Clinical Pharmacology and Therapeutics. 86: 519-526. PMID 19675541 DOI: 10.1038/Clpt.2009.141 |
0.355 |
|
| 2009 |
Zamboni WC, Ramalingam S, Friedland DM, Edwards RP, Stoller RG, Strychor S, Maruca L, Zamboni BA, Belani CP, Ramanathan RK. Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1466-72. PMID 19190127 DOI: 10.1158/1078-0432.Ccr-08-1405 |
0.419 |
|
| 2009 |
La-Beck NM, Zamboni BA, Tzemach D, Schmeeda H, Sapir R, Gabizon A, Zamboni WC. Evaluation of the relationship between patient factors and the reduction in clearance of pegylated liposomal doxorubicin Journal of Clinical Oncology. 27: 2548-2548. DOI: 10.1200/Jco.2009.27.15_Suppl.2548 |
0.38 |
|
| 2009 |
Wu H, Infante JR, Jones SF, Burris HA, Chan E, Keedy VL, Bendell JC, Zamboni BA, Kodaira H, Ikeda S, Zamboni WC. Abstract C127: Factors affecting the pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal irinotecan (IHL‐305) in patients with advanced solid tumors Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C127 |
0.373 |
|
| 2008 |
Zamboni W, Hwang JJ, Strychor S, Sidone BJ, Zamboni BA, Malik SM, Catley K, Grafton K, Marshall JL. Pharmacokinetic (PK) and pharmacodynamic (PD) study of the combination of docetaxel (Doc) and oxaliplatin (Ox) in patients (Pts) with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2546. PMID 27947935 DOI: 10.1200/Jco.2008.26.15_Suppl.2546 |
0.372 |
|
| 2008 |
Wonganan P, Zamboni WC, Strychor S, Dekker JD, Croyle MA. Drug-virus interaction: effect of administration of recombinant adenoviruses on the pharmacokinetics of docetaxel in a rat model. Cancer Gene Therapy. 16: 405-14. PMID 19110543 DOI: 10.1038/Cgt.2008.99 |
0.358 |
|
| 2008 |
Sivak WN, Pollack IF, Petoud S, Zamboni WC, Zhang J, Beckman EJ. LDI-glycerol polyurethane implants exhibit controlled release of DB-67 and anti-tumor activity in vitro against malignant gliomas. Acta Biomaterialia. 4: 852-62. PMID 18440882 DOI: 10.1016/J.Actbio.2007.10.012 |
0.352 |
|
| 2008 |
Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. The Oncologist. 13: 248-60. PMID 18378535 DOI: 10.1634/Theoncologist.2007-0180 |
0.401 |
|
| 2008 |
DeLoia JA, Zamboni WC, Jones JM, Strychor S, Kelley JL, Gallion HH. Expression and activity of taxane-metabolizing enzymes in ovarian tumors. Gynecologic Oncology. 108: 355-60. PMID 18063021 DOI: 10.1016/J.Ygyno.2007.10.029 |
0.347 |
|
| 2008 |
Thomas SM, Ogagan MJ, Freilino ML, Strychor S, Walsh DR, Gooding WE, Grandis JR, Zamboni WC. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Molecular Pharmacology. 73: 627-38. PMID 18025070 DOI: 10.1124/Mol.107.041160 |
0.36 |
|
| 2008 |
Zamboni WC, Strychor S, Joseph E, Parise RA, Egorin MJ, Eiseman JL. Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts. Cancer Chemotherapy and Pharmacology. 62: 417-26. PMID 17957368 DOI: 10.1007/S00280-007-0620-7 |
0.377 |
|
| 2007 |
Zamboni WC, Strychor S, Joseph E, Walsh DR, Zamboni BA, Parise RA, Tonda ME, Yu NY, Engbers C, Eiseman JL. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7217-23. PMID 18056203 DOI: 10.1158/1078-0432.Ccr-07-1035 |
0.381 |
|
| 2007 |
Loos WJ, Zamboni WC, Engels FK, de Bruijn P, Lam MH, de Wit R, Verweij J, Wiemer EA. Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel. Journal of Pharmaceutical and Biomedical Analysis. 45: 288-94. PMID 17804188 DOI: 10.1016/J.Jpba.2007.07.023 |
0.372 |
|
| 2007 |
Maruca LJ, Ramanathan RK, Strychor S, Zamboni BA, Ramalingam S, Edwards RP, Kim JK, Bang YJ, Lee HP, Zamboni WC. Age-related effects on the pharmacodynamic (PD) relationship between STEALTH liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors Journal of Clinical Oncology. 25: 2576-2576. DOI: 10.1200/Jco.2007.25.18_Suppl.2576 |
0.354 |
|
| 2007 |
Zamboni W, Maruca LJ, Strychor S, Zamboni BA, Ramalingam S, Edwards RP, Friedland DM, Stoller RG, Belani CP, Ramanathan RK. Age and body composition related-effects on the pharmacokinetic disposition of STEALTH liposomal CKD- 602 (S-CKD602) in patients with advanced solid tumors Journal of Clinical Oncology. 25: 2528-2528. DOI: 10.1200/Jco.2007.25.18_Suppl.2528 |
0.398 |
|
| 2007 |
Chen Y, Pandya KJ, Smudzin T, Strychor S, Sidone B, Zamboni WC. Phase II and pharmacokinetic (pk) study of induction docetaxel/cisplatin followed by pulsed docetaxel chemoradiation for stage III non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 25: 18142-18142. DOI: 10.1200/Jco.2007.25.18_Suppl.18142 |
0.344 |
|
| 2006 |
Akhavan A, McHugh KH, Guruli G, Bies RR, Zamboni WC, Strychor SA, Nelson JB, Pflug BR. Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia (New York, N.Y.). 8: 725-32. PMID 16984730 DOI: 10.1593/Neo.06388 |
0.339 |
|
| 2006 |
Patel H, Stoller R, Auber M, Potter D, Cai C, Zamboni W, Kiefer G, Matin K, Schmotzer A, Ramanathan RK. Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy. Investigational New Drugs. 24: 359-63. PMID 16525767 DOI: 10.1007/S10637-006-6451-2 |
0.38 |
|
| 2006 |
Zamboni WC, Ramanathan RK, McLeod HL, Mani S, Potter DM, Strychor S, Maruca LJ, King CR, Jung LL, Parise RA, Egorin MJ, Davis TA, Marsh S. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Investigational New Drugs. 24: 393-401. PMID 16505951 DOI: 10.1007/S10637-006-6335-5 |
0.32 |
|
| 2006 |
Zamboni WC, Goel S, Iqbal T, Parise RA, Strychor S, Repinski TV, Egorin MJ, Mani S. Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 57: 631-9. PMID 16205924 DOI: 10.1007/S00280-005-0084-6 |
0.356 |
|
| 2006 |
Zamboni WC, Friedland DM, Ramalingam S, Edwards RP, Stoller RG, Belani CP, Strychor S, Ou YC, Tonda ME, Ramanathan RK. Final results of a phase I and pharmacokinetic study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors Journal of Clinical Oncology. 24: 2013-2013. DOI: 10.1200/Jco.2006.24.18_Suppl.2013 |
0.417 |
|
| 2005 |
Zamboni WC. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8230-4. PMID 16322279 DOI: 10.1158/1078-0432.Ccr-05-1895 |
0.319 |
|
| 2005 |
Harrold JM, Eiseman JL, Joseph E, Strychor S, Zamboni WC, Parker RS. Control-relevant modeling of the antitumor effects of 9-nitrocamptothecin in SCID mice bearing HT29 human colon xenografts. Journal of Pharmacokinetics and Pharmacodynamics. 32: 65-83. PMID 16205839 DOI: 10.1007/S10928-005-2103-Y |
0.366 |
|
| 2005 |
Gillenwater HH, McCune JS, Lindley C, Faucette S, Shord S, Donahue A, Socinski MA, Stewart CF, Zamboni WC, Kirstein MN, Moore D. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. Cancer Investigation. 23: 511-9. PMID 16203659 DOI: 10.1080/07357900500201400 |
0.339 |
|
| 2005 |
Fakih MG, Creaven PJ, Ramnath N, Trump D, Javle M, Strychor S, Repinski TV, Zamboni BA, Schwarz JK, French RA, Zamboni WC. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5942-9. PMID 16115937 DOI: 10.1158/1078-0432.Ccr-05-0116 |
0.404 |
|
| 2005 |
Zamboni WC, Jung LL, Egorin MJ, Hamburger DR, Joseph E, Jin R, Strychor S, Ramanathan RK, Eiseman JL. Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 4867-74. PMID 16000585 DOI: 10.1158/1078-0432.Ccr-05-0144 |
0.4 |
|
| 2005 |
Posey JA, Wang H, Hamilton J, Delgrosso A, Zhang R, Freda T, Zamboni WC. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 56: 182-8. PMID 15838660 DOI: 10.1007/S00280-004-0925-8 |
0.408 |
|
| 2005 |
Ramanathan RK, Ramalingam S, Egorin MJ, Belani CP, Potter DM, Fakih M, Jung LL, Strychor S, Jacobs SA, Friedland DM, Shin DM, Chatta GS, Tutchko S, Zamboni WC. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology. 55: 354-60. PMID 15723261 DOI: 10.1007/S00280-004-0909-8 |
0.426 |
|
| 2005 |
Zamboni WC, Ramalingam S, Friedland DM, Belani CP, Stoller RG, Modi NB, Nath RP, Tonda ME, Strychor S, Ramanathan RK. Phase I and pharmacokinetic (PK) study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors Journal of Clinical Oncology. 23: 2069-2069. DOI: 10.1200/Jco.2005.23.16_Suppl.2069 |
0.437 |
|
| 2004 |
Ramanathan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, Earle M, Brufsky A, Evans T, Troetschel M, Walko C, Day R, Chen HX, Finkelstein S. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Investigation. 22: 858-65. PMID 15641483 DOI: 10.1081/Cnv-200039645 |
0.392 |
|
| 2004 |
Jung LL, Ramanathan RK, Egorin MJ, Jin R, Belani CP, Potter DM, Strychor S, Trump DL, Walko C, Fakih M, Zamboni WC. Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 54: 487-96. PMID 15322760 DOI: 10.1007/S00280-004-0835-9 |
0.388 |
|
| 2004 |
Stewart CF, Iacono LC, Chintagumpala M, Kellie SJ, Ashley D, Zamboni WC, Kirstein MN, Fouladi M, Seele LG, Wallace D, Houghton PJ, Gajjar A. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor Journal of Clinical Oncology. 22: 3357-3365. PMID 15310781 DOI: 10.1200/Jco.2004.10.103 |
0.428 |
|
| 2004 |
Zamboni WC, Jung LL, Egorin MJ, Potter DM, Friedland DM, Belani CP, Agarwala SS, Wong MM, Fakih M, Trump DL, Jin R, Strychor S, Vozniak M, Troetschel M, Ramanathan RK. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 5058-64. PMID 15297407 DOI: 10.1158/1078-0432.Ccr-03-0288 |
0.395 |
|
| 2004 |
Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Zuhowski EG, Pluim D, Joseph E, Hamburger DR, Working PK, Colbern G, Tonda ME, Potter DM, Eiseman JL. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemotherapy and Pharmacology. 53: 329-36. PMID 14673619 DOI: 10.1007/S00280-003-0719-4 |
0.368 |
|
| 2004 |
Goel S, Mani S, Iqbal T, Desai K, Parise RA, Afroze R, Egorin MJ, Zamboni WC. The effect of food on the oral absorption of 9-nitrocamptothecin (9NC) in patients with relapsed solid tumors Journal of Clinical Oncology. 22: 2106-2106. DOI: 10.1200/Jco.2004.22.90140.2106 |
0.355 |
|
| 2004 |
Chatta GS, Fakih M, Ramalingam S, Belani CP, Ramanathan RK, Zamboni W, Friedland D, Lis D, Tutchko S, Egorin M. Phase I pharmacokinetic (PK) study of daily imatinib in combination with docetaxel for patients with advanced solid tumors Journal of Clinical Oncology. 22: 2047-2047. DOI: 10.1200/Jco.2004.22.90140.2047 |
0.384 |
|
| 2004 |
Reddy NM, Zamboni WC, Creaven PJ, Ramnath N, Javle MM, Strychor S, Repinski TVW, Zamboni BA, Schwarz JK, French RA, Fakih MG. A phase I and pharmacokinetic (PK) study of weekly docetaxel (D), cisplatin (P), and daily capecitabine (C) (DPC) in patients with advanced solid tumors Journal of Clinical Oncology. 23: 2047-2047. DOI: 10.1200/Jco.2004.22.14_Suppl.2092 |
0.308 |
|
| 2003 |
Goel S, Bulgaru A, Hochster H, Wadler S, Zamboni W, Egorin M, Ivy P, Leibes L, Muggia F, Lockwood G, Harvey E, Renshaw G, Mani S. Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors Annals of Oncology. 14: 1682-1687. PMID 14581279 DOI: 10.1093/Annonc/Mdg453 |
0.381 |
|
| 2003 |
Parise RA, Ramanathan RK, Zamboni WC, Egorin MJ. Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 783: 231-6. PMID 12450543 DOI: 10.1016/S1570-0232(02)00659-1 |
0.313 |
|
| 2002 |
Zamboni WC, Stewart CE. An overview of the pharmacokinetic disposition of darbepoetin alfa. Pharmacotherapy. 22: 133S-140S. PMID 12222583 DOI: 10.1592/Phco.22.14.133S.33396 |
0.357 |
|
| 2001 |
Jung LL, Zamboni WC. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it? Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 4: 273-88. PMID 11998845 DOI: 10.1054/Drup.2001.0222 |
0.373 |
|
| 2001 |
Herrington JD, Figueroa JA, Kirstein MN, Zamboni WC, Stewart CF. Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction. Cancer Chemotherapy and Pharmacology. 47: 89-93. PMID 11221968 DOI: 10.1007/S002800000224 |
0.304 |
|
| 2001 |
Delauter BJ, Ramanathan RK, Egorin MJ, Stover LL, Zuhowski EG, Plunkett W, Zamboni WC. Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. Pharmacotherapy. 20: 1204-7. PMID 11034044 DOI: 10.1592/Phco.20.15.1204.34586 |
0.377 |
|
| 2000 |
Tkaczuk KH, Zamboni WC, Tait NS, Meisenberg BR, Doyle LA, Edelman MJ, Hausner PF, Egorin MJ, Echo DAV. Phase I study of docetaxel and topotecan in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 46: 442-448. PMID 11138457 DOI: 10.1007/S002800000180 |
0.358 |
|
| 2000 |
Zamboni WC, Egorin MJ, Van Echo DA, Day RS, Meisenberg BR, Brooks SE, Doyle LA, Nemieboka NN, Dobson JM, Tait NS, Tkaczuk KH. Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 3288-94. PMID 10986062 DOI: 10.1200/Jco.2000.18.18.3288 |
0.338 |
|
| 1999 |
Zamboni WC, Bowman LC, Tan M, Santana VM, Houghton PJ, Meyer WH, Pratt CB, Heideman RL, Gajjar AJ, Pappo AS, Stewart CF. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors Cancer Chemotherapy and Pharmacology. 43: 454-460. PMID 10321504 DOI: 10.1007/S002800050923 |
0.369 |
|
| 1999 |
Zamboni WC, Houghton PJ, Hulstein JL, Kirstein M, Walsh J, Cheshire PJ, Hanna SK, Danks MK, Stewart CF. Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemotherapy and Pharmacology. 43: 269-76. PMID 10071976 DOI: 10.1007/S002800050894 |
0.391 |
|
| 1998 |
Thompson J, Pratt CB, Stewart CF, Avery L, Bowman L, Zamboni WC, Pappo A. Phase I study of DMP 840 in pediatric patients with refractory solid tumors Investigational New Drugs. 16: 45-49. PMID 9740543 DOI: 10.1023/A:1006014510078 |
0.419 |
|
| 1998 |
Zamboni WC, Stewart CF, Thompson J, Santana VM, Cheshire PJ, Richmond LB, Luo X, Poquette C, Houghton JA, Houghton PJ. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. Journal of the National Cancer Institute. 90: 505-11. PMID 9539245 DOI: 10.1093/Jnci/90.7.505 |
0.349 |
|
| 1997 |
Stewart CF, Zamboni WC, Crom WR, Houghton PJ. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice Cancer Chemotherapy and Pharmacology. 40: 259-265. PMID 9219511 DOI: 10.1007/S002800050656 |
0.386 |
|
| 1997 |
Thompson J, Zamboni WC, Cheshire PJ, Richmond L, Luo X, Houghton JA, Stewart CF, Houghton PJ. Efficacy of oral irinotecan against neuroblastoma xenografts Anti-Cancer Drugs. 8: 313-322. PMID 9180383 DOI: 10.1097/00001813-199704000-00002 |
0.357 |
|
| 1997 |
Masson E, Zamboni WC. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Clinical Pharmacokinectics. 32: 324-343. PMID 9113440 DOI: 10.2165/00003088-199732040-00005 |
0.406 |
|
| 1996 |
Houghton PJ, Stewart CF, Zamboni WC, Thompson J, Luo X, Danks MK, Houghton JA. Schedule-dependent efficacy of camptothecins in models of human cancer Annals of the New York Academy of Sciences. 803: 188-201. PMID 8993512 DOI: 10.1111/J.1749-6632.1996.Tb26388.X |
0.307 |
|
| 1996 |
Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, Dryer ZA, Kurtzberg J, Bell B, Grier H, Vietti TJ. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. Journal of Pediatric Hematology/Oncology. 18: 352-61. PMID 8888741 DOI: 10.1097/00043426-199611000-00004 |
0.375 |
|
| 1996 |
Stewart CF, Zamboni WC, Crom WR, Gajjar A, Heideman RL, Furman WL, Meyer WH, Houghton PJ, Pratt CB. Topoisomerase I interactive drugs in children with cancer Investigational New Drugs. 14: 37-47. PMID 8880392 DOI: 10.1007/Bf00173681 |
0.365 |
|
| 1996 |
Zamboni W, Crom W, Bowman L, Pratt C, Houghton P, Stewart C. Interpatient variability in oral (PO) absorption of topotecan (TPT) in children with relapsed solid tumors. Clinical Pharmacology & Therapeutics. 59: 198-198. DOI: 10.1038/Sj.Clpt.1996.293 |
0.315 |
|
| Show low-probability matches. |